Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
NEW YORK, April 29, 2026 /PRNewswire/ -- IMPORTANT DATE: May 4, 2026. Investors who purchased Boston Scientific Corporation (NYSE: BSX) securities between July 23, 2025, and February 3, 2026, and wish to seek appointment as lead plaintiff must file a motion by this date. Start your claim now before the deadline. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
BSX shares fell $16.12 per share on February 4, 2026, a single-day decline of 17.6%, after the Company disclosed disappointing U.S. electrophysiology results and issued 2026 guidance far below expectations.
What is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995, any investor who purchased BSX securities during the Class Period may ask the Court to appoint them as lead plaintiff. The lead plaintiff selects counsel for the class, participates in key litigation decisions, and represents the interests of all class members. Courts generally appoint the applicant with the largest financial interest in the relief sought.
Lead Plaintiff Facts
Post-Deadline Procedures
After the May 4, 2026, deadline passes, the Court will review all motions and appoint the lead plaintiff it deems most adequate. The selected lead plaintiff and their chosen counsel then guide the litigation through discovery, class certification, and potential settlement or trial.
Absent Class Member Rights
Investors who do not seek lead plaintiff status remain absent class members. Absent class members are not responsible for litigation costs and retain the right to share in any recovery. No action is required to preserve your rights as an absent class member at this time, but investors who wish to have a voice in the direction of the litigation should consider applying before the deadline.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome. In the Boston Scientific action, where a single-day loss erased billions in market value, the Court will look for applicants whose losses reflect the magnitude of the alleged harm." — Joseph E. Levi, Esq.
About the BSX Class Action
A securities class action has been filed on behalf of purchasers of BSX common stock between July 23, 2025, and February 3, 2026. The action alleges that the Company and certain officers made materially misleading statements concerning the sustainability of the U.S. electrophysiology segment's growth trajectory, competitive positioning, and contribution to net income projections.
Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/bsx-investor-alert-boston-scientific-corporation-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-management-allegedly-hid-weakening-us-electrophysiology-sales-trends-levi--korsinsky-302756750.html
SOURCE Levi & Korsinsky
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
